Barbara Solecka-Witulska

Title: Innovations of Barbara Solecka-Witulska

Introduction

Barbara Solecka-Witulska is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of fusion proteins and glycosylated polypeptides. With a total of three patents to her name, her work has the potential to impact therapeutic applications significantly.

Latest Patents

One of her latest patents is focused on glycosylated VWF fusion proteins with improved pharmacokinetics. This invention relates to a fusion protein that comprises a main protein and one or more extension peptides. The amino acid sequence of the main protein is identical or similar to that of a mammalian protein, and the extension peptide contains a cluster of O-glycosylated amino acids. This fusion protein has an increased half-life compared to the main protein and may be used to enhance the half-life of a binding partner, such as FVIII. Another notable patent involves polypeptides that modulate SIGLEC dependent immune responses. This invention includes a glycosylated polypeptide that shows increased binding affinity to specific SIGLECs compared to the corresponding mammalian protein.

Career Highlights

Barbara Solecka-Witulska is currently associated with Octapharma AG, a company known for its focus on human proteins for therapeutic use. Her work at Octapharma AG has allowed her to explore innovative solutions in the biopharmaceutical sector.

Collaborations

She collaborates with esteemed colleagues such as Christoph Kannicht and Stefan Winge, contributing to a dynamic research environment that fosters innovation.

Conclusion

Barbara Solecka-Witulska's contributions to the field of biopharmaceuticals through her patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for advancements in therapeutic applications.